--- title: "Verastem | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 40.08 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/295150895.md" datetime: "2026-08-06T22:10:39.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/295150895.md) - [en](https://longbridge.com/en/news/295150895.md) - [zh-HK](https://longbridge.com/zh-HK/news/295150895.md) --- # Verastem | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 40.08 M Revenue: As of FY2026 Q2, the actual value is USD 40.08 M, beating the estimate of USD 22.88 M. EPS: As of FY2026 Q2, the actual value is USD -0.35, beating the estimate of USD -0.4378. EBIT: As of FY2026 Q2, the actual value is USD -31.96 M. ### Cash, Cash Equivalents, and Investments Verastem, Inc. reported cash, cash equivalents, and investments of $136.4 million at June 30, 2026, a decrease from $204.99 million at December 31, 2025. On a pro forma basis, including a $50.0 million non-dilutive royalty financing and a $15.0 million net sales milestone, cash, cash equivalents, and investments were $201.4 million as of June 30, 2026. ### Segment Revenue Total revenue for the three months ended June 30, 2026, was $40.1 million, a significant increase from $2.1 million for the same period in 2025. For the six months ended June 30, 2026, total revenue reached $58.749 million, compared to $2.137 million for the six months ended June 30, 2025. #### AVMAPKI® FAKZYNJA® CO-PACK Net Product Revenue Net product revenue was $25.1 million for the second quarter of 2026, up from $2.1 million in the second quarter of 2025. For the six months ended June 30, 2026, net product revenue was $43.749 million, compared to $2.137 million for the same period in 2025. #### Sale of COPIKTRA License and Related Assets Revenue Revenue from the sale of COPIKTRA license and related assets was $15.0 million for the second quarter of 2026, recognized after Secura Bio, Inc. achieved cumulative worldwide net sales of COPIKTRA exceeding $200.0 million. This revenue also amounted to $15.0 million for the six months ended June 30, 2026. ### Operating Expenses Total operating expenses for the three months ended June 30, 2026, were $72.8 million, an increase from $45.9 million for the same period in 2025. For the six months ended June 30, 2026, total operating expenses were $136.355 million, compared to $90.076 million for the same period in 2025. #### Breakdown of Operating Expenses (Three Months Ended June 30, 2026 vs. 2025) - **Cost of Sales - Product**: $3.762 million in 2026, compared to $0.318 million in 2025. - **Cost of Sales - Intangible Amortization**: $0.279 million in 2026, compared to $0.128 million in 2025. - **Research and Development Expenses**: $41.3 million in 2026, an increase of $16.5 million (67%) from $24.8 million in 2025, primarily due to increased investigator fees, CRO costs, drug product manufacturing, and personnel costs. - **Selling, General and Administrative Expenses**: $27.4 million in 2026, an increase of $6.7 million (32%) from $20.7 million in 2025, mainly due to higher personnel costs and commercial operations. ### Profitability #### Loss from Operations Loss from operations was -$32.710 million for the three months ended June 30, 2026, an improvement from -$43.764 million for the same period in 2025. #### Net Loss (GAAP basis) GAAP net loss was -$34.7 million for the three months ended June 30, 2026, compared to -$25.9 million for the same period in 2025. For the six months ended June 30, 2026, GAAP net loss was -$71.264 million, compared to -$78.037 million for the same period in 2025. #### Non-GAAP Adjusted Net Loss Non-GAAP adjusted net loss was -$30.6 million for the three months ended June 30, 2026, compared to -$41.3 million for the same period in 2025. For the six months ended June 30, 2026, non-GAAP adjusted net loss was -$73.325 million, compared to -$84.192 million for the same period in 2025. ### Other Financial Items (Three Months Ended June 30, 2026 vs. 2025) - **Interest Income**: $1.108 million in 2026, compared to $0.822 million in 2025. - **Interest Expense**: -$0.360 million in 2026, compared to -$0.212 million in 2025. - **Income Tax Expense**: -$0.816 million in 2026. - **Change in Fair Value of Notes**: -$1.843 million in 2026, compared to -$2.990 million in 2025. ### Outlook / Guidance Verastem, Inc. anticipates that its pro forma cash position, combined with expected product revenue and a future tranche from the Oberland facility, will extend its cash runway into the second half of 2027. Key milestones for AVMAPKI FAKZYNJA CO-PACK include a topline readout of the RAMP 301 trial’s primary endpoint in mid-2027 and continued regulatory pursuit in Europe and Japan. For VS-7375, the company expects updated clinical data in October 2026, completion of enrollment across all three TARGET-D Phase 2 trials by year-end 2026, and the start of Phase 3 pivotal trials in the first half of 2027. ### Related Stocks - [VSTM.US](https://longbridge.com/en/quote/VSTM.US.md) ## Related News & Research - [Verastem (NASDAQ:VSTM) Posts Earnings Results, Beats Estimates By $0.08 EPS](https://longbridge.com/en/news/295282473.md) - [Verastem Q2 revenue jumps on new product sales and milestone](https://longbridge.com/en/news/295138125.md) - [BUZZ-Verastem rises after FDA grants fast-track status for cancer drug](https://longbridge.com/en/news/288624729.md) - [BUZZ-Verastem rises as combo therapy shows early benefit in pancreatic cancer](https://longbridge.com/en/news/290045980.md) - [Verastem Q4 2025 earnings preview](https://longbridge.com/en/news/277689117.md)